吸入变应原皮下注射集群免疫治疗专家共识  

Expert consensus on subcutaneous cluster immunotherapy of inhaled allergens

作　　者：中国康复医学会变态反应性疾病康复专业委员会 北京慢性病防治与健康教育研究会变态反应学专业委员会 关凯 祝戎飞 李丽莎 陈浩[3] Committee on Allergy,Chinese Association of Rehabilitation Medicine;Committee on Allergy,Beijing Research Association for Chronic Diseases Control and Health Education;Guan Kai;Zhu Rongfei(不详;Department of Allergy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease,National Clinical Research Center for Dermatologic and Immunologic Diseases,Beijing 100730,China;Department of Allergy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030)

机构地区：[1]不详 [2]中国医学科学院北京协和医学院北京协和医院变态(过敏)反应科,过敏性疾病精准诊疗研究北京市重点实验室,国家皮肤与免疫疾病临床医学研究中心,北京100730 [3]华中科技大学同济医学院附属同济医院过敏反应科,武汉430030

出　　处：《中华预防医学杂志》2024年第12期1825-1834,共10页Chinese Journal of Preventive Medicine

基　　金：国家自然科学基金面上项目(82370041,82070033);北京市自然科学基金面上项目(7222136);中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-107);中央高水平医院临床科研业务费(2022-PUMCH-B-088,2022-PUMCH-B-089)。

摘　　要：变应原特异性免疫治疗是目前唯一能够阻止过敏性疾病病情进展的对因治疗方法。集群免疫治疗是一种改良免疫治疗方案,将剂量递增期从常规方案的4~6个月缩短为1~8周。既往我国尚无指导吸入变应原皮下注射集群免疫治疗规范化应用的共识指南,本共识基于国内外相关研究证据,结合行业专家观点,系统阐述了集群免疫治疗的适应证与禁忌证,提出集群方案起效早于常规方案,两者引起全身过敏反应的发生率相似;同时还强调了集群免疫治疗所致全身过敏反应的危险因素以及防治措施。本共识旨在提高我国医护人员对于集群免疫治疗的认识水平,指导集群免疫治疗的规范化应用与管理。Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present.Cluster immunotherapy is an improved immunotherapy regimen,which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks.In the past,there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China.Based on relevant research evidence at home and abroad and the opinions of industry experts,this consensus systematically expounded the indications and contraindications of cluster immunotherapy,and proposed that the cluster scheme took effect earlier than the conventional scheme,with similar incidence of systemic allergic reaction with the conventional scheme.At the same time,the risk factors and preventive measures of systemic allergic reaction caused by cluster immunotherapy were emphasized.This consensus aims to improve the understanding of cluster immunotherapy among medical staff in China and guide the standardized application and management of cluster immunotherapy.

关 键 词：变应原特异性免疫治疗 集群免疫治疗 疗效 安全性 危险因素 

分 类 号：R593.1[医药卫生—内科学]